Renovaro's AI-Driven Cancer Diagnostics Subsidiary Receives EU Funding and New Leadership

Eurostars Funding Approval for Lumina Project

Renovaro Inc. (NASDAQ: RENB), a pioneer in AI-powered cancer diagnostics and therapeutics, has announced that its subsidiary RenovaroCube, along with consortium partners Flomics Biotech, Uppsala Universitet, and Oncodia, has received grant funding approval for the Lumina project from the Eurostars funding program 1

1

. Eurostars, part of the European Partnership on Innovative SMEs, is co-funded by the European Union through Horizon Europe and represents a significant investment in innovative R&D projects 2

2

.

The Lumina Project: Advanced Cancer Detection

The Lumina project aims to develop an advanced Minimal Residual Disease (MRD) detection platform for lung cancer. This cutting-edge platform harnesses the power of multi-omics biomarkers and AI-driven technology to transform recurrence risk prediction and treatment strategies for millions of patients worldwide 1

1

.

David Weinstein, CEO of Renovaro, emphasized the project's significance: "Over 5 million lung cancer cases are treated or monitored globally each year, and 60% of curatively treated lung cancer patients will relapse. Lumina represents a significant opportunity to address this critical issue." 2

2

RenovaroCube's AI Platform

RenovaroCube's AI platform is purpose-built to process and analyze multi-omic molecular data, facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization. The platform offers:

1. Sequence Processing: Transforming raw molecular data into analyzable formats.
2. Discovery: Identifying biologically relevant cancer biomarkers.
3. Factory: Employing machine learning models to predict cancer presence, origin, and stage.
4. Diagnostics: Providing an interactive interface for data visualization and clinical reporting 1

   1

   .

New Leadership for RenovaroCube

In a strategic move, Renovaro Inc. has appointed Maurice van Tilburg as Chief Executive Officer of GEDi Cube BV (operating as RenovaroCube) 3

3

. Van Tilburg, who currently serves as Renovaro's Chairman of the Board, brings extensive experience from the financial services and technology sectors 4

4

.

David Weinstein commented on the appointment: "His expertise in technology and the capital markets will enable us to prioritize commercializing our technologies." Van Tilburg expressed enthusiasm for his new role, stating, "I believe that the transformative AI Cube platform will be an inflection point in the creation of diagnostics for early-stage cancer and identifying new genes for our Cancer Vaccine Platform." 3

3

Financial Outlook and Market Position

As of the latest reports, Renovaro Inc. has a market capitalization of $146 million, with its stock trading near $0.92. The company faces some financial challenges, with short-term obligations exceeding liquid assets and a current ratio of 0.08 4

4

. However, recent developments, including regaining Nasdaq compliance and strategic partnerships, indicate efforts to strengthen its market position and advance its technological objectives.